Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (1): 29-35.doi: 10.12092/j.issn.1009-2501.2023.01.004

Previous Articles     Next Articles

Effect of Atglistatin on PA-induced VSMCs proliferation and ATGL expression

TANG Zizhao, NIE Fangqin, YAN Xin, FU Yangxia, HUANG Jun, WANG Xia, GUO Ren   

  1. The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China
  • Received:2021-11-03 Revised:2022-10-09 Online:2023-01-26 Published:2023-02-14

Abstract:

AIM: With building a proliferation model of PA-induced VSMC, the effect of ATGL, a key fat metabolism enzyme, on the phenotype transformation of VSMC was preliminarily explored.  METHODS: 40 μmol/L Atglistatin was added to the proliferation model of VSMC induced by PA (50 μmol/L, 100 μmol/L, and 200 μmol/L, respectively) at separately administered concentrations, and cell viability and cell proliferation were detected by CCK-8 and EDU; cell migration ability was detected by scratch assay; oil red staining was used to detect the accumulation of lipid droplets in VSMC was detected by oil red staining; the effects of PA on ATGL as well as the effects of smooth muscle contraction phenotype proteins were examined by Western blot. RESULTS: PA at a concentration of 100 μmol/L could significantly induce VSMC proliferation, promote lipophagy and increase lipid droplet accumulation in VSMC; meanwhile, Atglistatin could exacerbate these changes caused by PA and increase lipid droplet accumulation in VSMC.CONCLUSION: Atglistatin exacerbates PA-induced VSMC proliferation and increases VSMC lipid droplet accumulation, and exacerbates transformation of proliferative phenotype of VSMC.

Key words: palmitic acid, adipose triglyceride lipase, arteriosclerosis, Atglistatin, lipid droplet

CLC Number: